BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that its Head of Technical R&D, Dr. Dalit Weinstein Fischer, will attend and present at Recent Advances in Fermentation Technology (“RAFT”) 14. The conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”) is taking place from Nov. 6 to 9, 2022, in Orlando, Florida. RAFT provides academic and industrial scientists a forum to discuss the latest developments in fermentation technology. Dr. Fischer’s presentation, slated to begin at 3:35 p.m. ET on Nov. 8, will focus on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (“NanoAbs”). BiondVax’s lead NanoAb candidate, for treatment of COVID-19, exhibits significant competitive advantages over currently available monoclonal antibody (“mAbs”) and oral COVID-19 therapies. Development is also underway for additional NanoAbs that address diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis and asthma.
To view the full press release, visit https://nnw.fm/kqwHm
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork